<DOC>
	<DOC>NCT00300274</DOC>
	<brief_summary>This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.</brief_summary>
	<brief_title>Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male or female cardiac recipients 1870 years of age undergoing primary heart transplantation. The graft must be functional at time of randomization. Patients who are recipients of multiple solid organ transplants or tissue transplants or have previously received organ transplants. Patients who are recipients of ABO incompatible transplants. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>heart transplant</keyword>
	<keyword>heart disease</keyword>
	<keyword>transplantation</keyword>
	<keyword>heart IVUS assessment at 12 months</keyword>
	<keyword>rate of graft loss</keyword>
	<keyword>acute rejection episodes</keyword>
	<keyword>survival</keyword>
</DOC>